Clinical trials: Metformin
Type 2 Diabetes Mellitus
Dose-Ranging Study Evaluating AVE2268 in Patients With Type 2 Diabetes Not Adequately Controlled by a Metformin Treatment
Dose-ranging study of AVE2268 in the management of patients with type 2 diabetes mellitus also receiving metformin. Its main objectives will be to assess the effects of several doses of AVE2268 on Mean Plasma Glucose.
- Trial name
- NCT00361738
- Testing
- AVE2268
- Where
- 11 sites in Argentina, Australia and 9 more
- Volunteers
- 317 people
- Sponsor
- Sanofi
Type 2 Diabetes Mellitus
Efficacy and Safety of Alogliptin Used Combination With Metformin in Participants With Type 2 Diabetes in Japan
The purpose of this study was evaluate the efficacy and safety of alogliptin, once dairy (QD) combined with metformin taken twice daily (BID) or three times daily (TID) in type 2 diabetic patients with uncontrolled blood glucose.
- Trial name
- NCT01318109
- Testing
- Alogliptin and metformin, Metformin
- Volunteers
- 288 people
- Sponsor
- Takeda
Diabetes Mellitus, Type 2
Diabetes Study of Linagliptin and Empagliflozin in Children and Adolescents (DINAMO)TM
The purpose of this research study is to evaluate the efficacy and safety of an empagliflozin dosing regimen and one dose of linagliptin in patients with type 2 diabetes who are aged 10 to below 18 years and are currently taking…
- Trial name
- NCT03429543
- Testing
- Metformin, Insulin, Linagliptin
- Where
- 83 sites in United States, Argentina and 12 more
- Volunteers
- 175 people
- Sponsor
- Boehringer Ingelheim
Diabetes Mellitus, Non-Insulin-Dependent
Addition Of Januvia (Sitagliptin) Improves Glycemic Control In Patients Inadequately Controlled By Metformin (MK0431-078)
To compare the efficacy of three strategies of lifestyle changes associated with Januvia (sitagliptin) 100 mg/day in patients with Type 2 Diabetes Mellitus (T2DM) inadequately controlled by metformin (hemoglobin A1c [HbA1c]…
- Trial name
- NCT00545584
- Testing
- sitagliptin phosphate, Comparator: Diet, Comparator: Physical Activity
- Volunteers
- 1,512 people
- Sponsor
- Merck Sharp & Dohme LLC
Healthy Volunteers
A Study to Compare MP-513 20mg & Metformin XR 1000mg FDC With Coadministration of the Two Separate Drugs
The purpose of this study is to compare the safety and pharmacokinetic characteristics of fixed-dose combination of MP-513 20mg and Metformin XR 1000mg with coadministration of the two separate drugs in healthy male volunteers.
- Trial name
- NCT03787017
- Testing
- FDC(MP-513 20mg/Metformin XR 1000mg), MP-513 20mg, Metformin XR 1000mg
- Where
- South Korea
- Volunteers
- 36 people, healthy volunteers welcome
- Sponsor
- Handok Inc.
Type 2 Diabetes Mellitus
A Study To Evaluate The Efficacy And Safety Of Ertugliflozin In Participants With Type 2 Diabetes Mellitus And Inadequate Glycemic Control On Metformin Monotherapy (MK-8835-007).
This is an efficacy and safety study of ertugliflozin in participants with type 2 diabetes mellitus (T2DM) and inadequate glycemic control on metformin monotherapy.
- Trial name
- NCT02033889
- Testing
- Ertugliflozin 5 mg, Ertugliflozin 15 mg, Glimepiride
- Volunteers
- 621 people
- Sponsor
- Merck Sharp & Dohme LLC
Diabetes Mellitus, Type 2
A Study in Type 2 Diabetic Subjects on Stable Metformin Therapy to Investigate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Co-administering Single and Multiple Oral Doses of GSK1292263
A study in type 2 diabetic subjects on stable metformin therapy to investigate the safety, tolerability, pharmacokinetics and pharmacodynamics of co-administering single and multiple oral doses of GSK1292263
- Trial name
- NCT01128621
- Testing
- GSK1292263, Sitagliptin
- Where
- 2 sites in United States
- Volunteers
- 66 people
- Sponsor
- GlaxoSmithKline
Diabetes Mellitus, Type 2
Study Of Safety And Efficacy Of Ertugliflozin (PF-04971729, MK-8835) In Participants With Type 2 Diabetes (MK-8835-016)
MK-8835-016 (B1521006) is designed to evaluate the safety and efficacy of an investigational drug, ertugliflozin (MK-8835, PF-04971729) in participants with Type 2 diabetes mellitus.
- Trial name
- NCT01059825
- Testing
- Ertugliflozin 1 mg, Ertugliflozin 5 mg, Ertugliflozin 25 mg
- Volunteers
- 375 people
- Sponsor
- Merck Sharp & Dohme LLC
Healthy
A Relative Bioavailability Study of Metformin HCl 750 mg ER Tablets Under Non-fasting Conditions
The purpose of this study is compare the relative bioavailability of 750 mg Metformin Hydrochloride Extended Release Tablets by Purepac Pharmaceutical Co with that of 750 mg GLUCOPHAGE® XR Tablets by Bristol-Myers Squibb Company…
- Trial name
- NCT00865852
- Testing
- Metformin HCl 750 mg Extender Release tablets, single dose, GLUCOPHAGE® XR 750 mg tablets, single dose
- Where
- United States
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Actavis Inc.
Healthy
A Study to Assess the Bioequivalence of 2 Fixed Dose Combination (FDC) Tablets of Canagliflozin and Metformin Immediate Release (IR) (50 mg/1,000 mg) With Respect to the Individual Components of Canagliflozin (1 x 100 mg) and Metformin IR Tablets (2 x 1,000 mg) in Healthy Volunteers
The purpose of this study is to evaluate the bioequivalence of fixed dose combination (FDC) tablets of canagliflozin and metformin immediate release (IR) in comparison with the individual components of canagliflozin and metformin…
- Trial name
- NCT01454622
- Testing
- A (canagliflozin and metformin IR individual tablets) / B (canagliflozin/metformin IR FDC tablets), B (canagliflozin/metformin IR FDC tablets / A (canagliflozin and metformin IR individual tablets)
- Where
- United States
- Volunteers
- 64 people, healthy volunteers welcome
- Sponsor
- Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Type 2 Diabetes (Treated With Exenatide or Other Oral Antidiabetic Therapies), Healthy Subjects (Treated With no Diabetes Therapies)
A Retrospective Cohort Study of Acute Pancreatitis in Relation to Use of Exenatide and Other Antidiabetic Agents
The purpose of this research was to assess the absolute and relative incidence of acute pancreatitis in persons initiating exenatide compared with persons initiating a different antidiabetic agent, and secondarily, persons…
- Trial name
- NCT01077323
- Testing
- exenatide, Other antidiabetic therapies, No diabetes therapy
- Where
- United States
- Volunteers
- 363,766 people
- Sponsor
- AstraZeneca
Diabetes Mellitus, Type 2
Linagliptin and Metformin Versus Linagliptin in Newly Diagnosed, Untreated Type 2 Diabetes
The purpose of this trial is to determine whether a initial combination of linagliptin and metformin compared to linagliptin alone for 24 weeks is effective in newly diagnosed, treatment-naïve patients with Type 2 Diabetes.
- Trial name
- NCT01512979
- Testing
- metformin, linagliptin
- Where
- 82 sites in United States, Canada and 10 more
- Volunteers
- 316 people
- Sponsor
- Boehringer Ingelheim
Diabetes Mellitus, Type 2
Long-term Efficacy and Safety of HMS5552 add-on to Metformin in T2DM Subjects
This study evaluates the efficacy and safety and population PK of HMS5552 add-on to Metformin in adult type 2 diabetic subjects.
- Trial name
- NCT03141073
- Testing
- HMS5552
- Where
- China
- Volunteers
- 767 people
- Sponsor
- Hua Medicine Limited
To Determine Bioequivalence Under Fed Conditions
The Study Aims to Show Bioequivalence of the Test Product and the Reference Reference Product in a Crossover Design Study Healthy Volunteers. Additionally, the Safety Profile of Test Product Compared to Reference Product Will be Assessed.
To evaluate and compare the relative bioavailability and therefore the bioequivalence of fixed dose combination of Metformin and Vildagliptin Tablets 850/50 mg manufactured by Oman Pharmaceuticals Products Co.
- Trial name
- NCT05337969
- Testing
- Metformin and Vildagliptin 850/50 mg
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- AET Laboratories Private Limited
Breast Cancer, Solid Tumor
To Evaluate the Safety, Tolerability, and Pharmacokinetics of Inavolisib Single Agent in Participants With Solid Tumors and in Combination With Endocrine and Targeted Therapies in Participants With Breast Cancer
This is an open-label, multicenter, Phase I study designed to evaluate the safety, tolerability, and pharmacokinetics of inavolisib administered orally as a single agent in patients with locally advanced or metastatic…
- Trial name
- NCT03006172
- Testing
- Inavolisib, Fulvestrant, Letrozole
- Where
- 12 sites in United States, Canada and 3 more
- Volunteers
- 200 people
- Sponsor
- Genentech, Inc.
Diabetes Mellitus, Type 2
A Research Study to Compare Two Types of Insulin: Insulin 287 and Insulin Glargine in People With Type 2 Diabetes Who Have Not Used Insulin Before
This study compares insulin 287 (a possible new medicine) to insulin glargine (a medicine doctors can already prescribe) in people with type 2 diabetes. Different ways of changing the dose of insulin 287 are also compared.
- Trial name
- NCT03951805
- Testing
- Insulin icodec, Insulin Glargine
- Where
- 43 sites in United States, Croatia and 5 more
- Volunteers
- 205 people
- Sponsor
- Novo Nordisk A/S
Type 2 Diabetes Mellitus
A Study of Oral GLP1RA RGT001-075 in Adults With Type 2 Diabetes
This is a phase 2 study designed to evaluate the efficacy of daily (QD) oral RGT001-075 GLP1 receptor agonist relative to placebo after up to 16 weeks of double-blind treatment as determined by mean change from baseline in HbA1c…
- Trial name
- NCT05297045
- Testing
- RGT001-075
- Where
- United States
- Volunteers
- 17 people
- Sponsor
- Regor Pharmaceuticals Inc.
Diabetes Mellitus, Type 2
A Sub-study to LMF237A2302 to Assess the Effect of 24 Weeks Treatment With Initial Combination of Vildagliptin Plus Metformin
This study will evaluate the effects of treatment with vildagliptin and metformin as initial combination in newly diagnosed patients with type 2 diabetes who have very high levels of HbA1c and/or fasting plasma glucose.
- Trial name
- NCT00468039
- Testing
- vildagliptin + metformin
- Where
- United States
- Volunteers
- 94 people
- Sponsor
- Novartis
Diabetes Mellitus, Type 2
A Trial of TT223 in Patients With Type 2 Diabetes Who Are Taking Metformin and/or Thiazolidinedione
This trial is designed to show the effect of treatment with TT223 or placebo on blood glucose control after 12 weeks of treatment with a 6 month follow-up.
- Trial name
- NCT00743002
- Testing
- TT223 with Metformin and/or TZD
- Where
- 20 sites in United States
- Volunteers
- 87 people
- Sponsor
- OPKO Health, Inc.
Type 2 Diabetes
A Study to Evaluate ITCA 650 Compared to Sitagliptin as add-on Therapy for the Treatment of Type 2 Diabetes
Phase 3 study to compare treatment with ITCA 650 to sitagliptin when added to metformin monotherapy in patients with type 2 diabetes.
- Trial name
- NCT01455870
- Testing
- ITCA 650 60 mcg/day, sitagliptin
- Where
- 54 sites in United States, Croatia and 3 more
- Volunteers
- 535 people
- Sponsor
- Intarcia Therapeutics